Home・Stock List・Corcept Therapeutics Inc

Corcept Therapeutics Inc

Closed

SectorHealthcare

114.39 3.94

Buy Sell

Overview

Share price change

24h

Current

Min

109.9

Max

114.76

Key metrics
By Trading Economics
Income	75M 43M
Sales	91M 256M
P/E Sector Avg	243.043 57.002
EPS	0.36
Profit margin	16.782
Employees	730
EBITDA	91M 47M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+18.15% upside

Dividends
By Acuity
Next Earnings	3 Nov 2026

Market Stats
By TradingEconomics
Market Cap	2.6B 12B
Previous open	110.45
Previous close	114.39

News Sentiment

By Acuity

50%

163 / 340 Healthcare

Corcept Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

13 Aug 2026, 19:46 UTC

Corcept Therapeutics Inc is declining today, with no specific news identified. The stock peaked earlier but has since retraced from that high.

12 Aug 2026, 19:16 UTC

Corcept Therapeutics Inc shares are higher today amid a positive trend in U.S. stocks, despite geopolitical tensions and rising crude oil prices.

11 Aug 2026, 20:06 UTC

Corcept Therapeutics Inc. shares are lower today, having declined steadily after reaching a session high earlier. The stock remains above its 20-day moving average.

10 Aug 2026, 19:16 UTC

Corcept Therapeutics Inc shares are higher today, recovering from an early drop despite a broader market decline amid labor market concerns.

7 Aug 2026, 21:01 UTC

Corcept Therapeutics Inc shares are lower in after-market trading, declining despite being above its 20-day moving average and near the upper end of its one-month range.

5 Aug 2026, 19:56 UTC

Corcept Therapeutics Inc's shares are higher today, reflecting a generally positive market environment. The stock remains significantly above its 20-day moving average.

4 Aug 2026, 19:16 UTC

Corcept Therapeutics Inc shares are lower today, continuing a decline seen over the past three trading days. No specific news was identified for the drop.

3 Aug 2026, 20:02 UTC

Corcept Therapeutics Inc shares are lower today amid a decline in the Pharmaceuticals sub-sector, with unusually high trading volume noted.

31 Jul 2026, 22:26 UTC

Corcept Therapeutics shares are higher in after-market hours, peaking shortly after Friday's close despite no specific news to explain the movement.

30 Jul 2026, 23:11 UTC

Corcept Therapeutics shares traded lower in after-market hours, reflecting broader market uncertainty following the Federal Reserve's interest rate decision.

29 Jul 2026, 23:41 UTC

Social Media

News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

28 Jul 2026, 19:46 UTC

News

Corcept Therapeutics shares are higher ahead of Q2 earnings tomorrow, with analysts expecting revenue growth to slow to 8.4% year-on-year.

27 Jul 2026, 23:46 UTC

Shares of Corcept Therapeutics Inc declined in after-hours trading, dipping to a low shortly after the market reopened. No specific news was identified.

24 Jul 2026, 21:01 UTC

Corcept Therapeutics shares are lower in after-market trading, reflecting broader negative sentiment following earnings reports from major companies like Tesla and Alphabet.

22 Jul 2026, 19:51 UTC

Corcept Therapeutics Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is affected by rising crude oil prices and geopolitical tensions.

21 Jul 2026, 17:06 UTC

Corcept Therapeutics Inc is trading higher today, reflecting broader market trends as regional indices like the Nikkei 225 also show gains.

20 Jul 2026, 18:13 UTC

Social Media

Corcept Therapeutics shares are higher today, boosted by FDA approval of Lifyorli and increased trading volume amid heightened investor interest.

Peer Comparison

Price change

Corcept Therapeutics Inc Forecast

Price Target

By TipRanks

18.15% upside

12 Months Forecast

Average 135.25 USD 18.15%

High 165 USD

Low 50 USD

Based on 4 Wall Street analysts offering 12 month price targets forCorcept Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Corcept Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

163 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.